MedTech Brand Launch Playbook for Startups

What This Template Includes

A 90-day operational launch playbook structured for MedTech startups bringing their first commercial product to market. The playbook is sequenced into three 30-day phases — Pre-Launch, Launch, Post-Launch Stabilization — with deliverables, owners, decision points, and operational checklists for each phase.

The pack includes:

• Day-by-day milestone calendar for the 90-day window
• Brand identity worksheet for first-product positioning
• Sales enablement asset list with structure templates for each asset
• Channel readiness checklist for hospital, IDN, distributor, and direct-customer channels
• First 10 customer playbook for executing initial commercial deployments
• Launch metrics dashboard template for tracking 90-day performance

Who This Is For

• MedTech startups bringing their first commercial product to market post-clearance
• Companies expanding from research-only or clinical-trial-only to commercial sales
• Established companies launching a meaningfully differentiated new product line
• Regulatory affairs and clinical teams who need to coordinate with marketing/sales for launch

Companies launching their 5th or 50th product have institutional launch playbooks already. This template is for teams without that institutional infrastructure.

The Pre-Launch Phase (Days -30 to 0)

Before launch day, the company is in commercial preparation. Approval is in hand or imminent; the commercial team is staffing up; assets are being produced.

Brand Identity Worksheet

• Primary positioning statement drafted (what this product is, who it's for, what's different)
• Visual identity finalized (logo, color, type, photography style)
• Brand voice and tone documented
• Approved product name confirmed (regulatory + trademark cleared in launch markets)
• Tagline drafted (memorable + regulation-compliant)
• Competitive positioning matrix completed
• Brand assets organized in single canonical repository (DAM or shared drive)

Sales Enablement Assets

The minimum viable sales enablement pack for a Class II MedTech product:

1. Master pitch deck (15–20 slides) — clinical context, product overview, evidence, customer profile, pricing, implementation timeline
2. Detail aid (6–10 page visual aid) — for in-office and in-clinic conversations
3. Product brochure (4–8 pages) — leave-behind for prospects
4. Evidence summary (2–4 pages) — clinical and economic evidence in citation-ready format
5. Case studies (2–3 written customer stories from pilot deployments or clinical sites)
6. Pricing and procurement guide (internal-only) — how the product is sold, contracted, invoiced
7. Objection handling guide (internal-only) — anticipated objections and responses
8. Demo script and protocol — for product demonstrations in clinical and commercial settings

For regulated markets (US, EU, Korea), all customer-facing assets above require regulatory review before distribution. Budget 2–4 weeks of regulatory review time into the asset production timeline.

Channel Readiness

The launch channel mix typically includes some combination of:

• Direct sales force (employed reps)
• Distributor partners
• IDN/group purchasing organization (GPO) contracts
• E-commerce or digital ordering (for lower-complexity products)
• Strategic clinical partnerships (academic medical centers as reference accounts)

The pre-launch checklist for each channel:

Direct sales:

• Sales team hired and trained
• Territory assignments finalized
• CRM configured
• Compensation plan documented
• First-week call lists prepared

Distributor:

• Distribution agreements signed
• Distributor sales teams trained
• Distributor inventory levels confirmed
• Co-marketing materials approved

IDN/GPO:

• Contract templates approved by legal
• Pricing tiers documented
• Compliance review (Sunshine Act, GPO disclosure) complete

E-commerce:

• Ordering platform live
• Payment processing configured
• Inventory integration with fulfillment confirmed

Regulatory Cleanup

Pre-launch is also when regulatory cleanup happens — making sure everything that should be in place actually is.

• Final regulatory clearance in hand for all launch markets
• UDI database registrations complete
• Labeling printed and approved
• Distribution license verified per market
• First-shipment customs clearance pre-arranged
• Vigilance reporting procedures activated
• Complaint handling system live

The Launch Phase (Days 0–30)

Launch day is not a single event; it is a 30-day window during which the product transitions from "available" to "actively sold."

Day 0–7: Internal Launch

The first week is internal alignment, not external announcement. Specifically:

• All-hands product update
• Sales team final certification (each rep can deliver the demo)
• Customer support team trained on troubleshooting
• Inventory in distributor warehouses
• First-week metrics dashboard live

Day 7–14: Targeted External Launch

The first external activation is targeted, not broad. Specifically:

• Reference customer announcements (pre-launch pilot accounts now publicly identified)
• Industry/trade media outreach (embargo to coordinated announcement date)
• Direct outreach to top-priority prospects (warm leads from clinical/regulatory work)
• First conference or trade show presence

Day 14–30: Broader Activation

The remainder of the 30-day launch window is broader market activation:

• Public website launch with product pages
• Social media activation
• Paid search and advertising (if part of the plan)
• Educational content (webinars, surgical technique videos for HCP-targeted products)
• KOL engagement (clinical advisors publicly endorsing the product)

The Post-Launch Stabilization Phase (Days 31–90)

After the launch sprint, the company moves to stabilization — converting initial interest into repeatable commercial operations.

The First-10-Customer Playbook

The first ten commercial customers shape everything downstream. Their experience determines whether the launch builds positive momentum or stalls. Specific operational practices for the first ten:

• Senior leadership personally engaged with each (CEO or commercial leader involvement)
• Implementation supported by clinical team, not just sales
• Customer success metrics tracked weekly per account
• Case study development planned during onboarding (not bolted on after)
• Reference call commitment requested as part of onboarding (consent to be a reference)
• Net Promoter Score or equivalent feedback collected at 30 and 60 days

Operational Stabilization

• Sales rep daily call patterns established
• CRM data hygiene reviewed weekly
• Quote-to-order conversion rate measured
• Inventory burn rate stabilized
• Distributor performance reviewed (if multi-distributor)
• Customer onboarding time-to-value measured

Marketing Stabilization

• Content cadence established (weekly content publication target)
• SEO performance measured
• Paid acquisition cost-per-customer measured
• Trade show calendar locked for next 6 months
• HCP engagement program structured (advisory board, journal sponsorships, educational events)

Launch Metrics That Matter

A short list of metrics worth tracking through the 90-day window:

Metric	Target by Day 30	Target by Day 90
Qualified leads generated	Baseline	3-5× baseline
Quotes issued	Baseline	2-3× baseline
Orders placed	First few	Repeatable cadence
Customer acquisition cost	Estimate	Within 30% of target
Customer onboarding time	Variable	Standardized SLA
Customer NPS at 30 days	Baseline	Established baseline
Distributor monthly volume	Initial stocking	Stabilized run-rate
Field issues per 100 units sold	Baseline	Decreasing trend

Vanity metrics (press impressions, social media followers) are tracked but should not drive decisions in the first 90 days.

Launch Failure Modes

Three patterns that consistently undermine MedTech launches:

Failure 1: Sales team launched before they can demonstrate. A rep who cannot deliver the demo confidently does damage in the first 90 days. Hold the launch by 30–60 days rather than launch with unprepared reps.

Failure 2: Distributor without internal champion. A distributor "carrying" the product without a sales rep specifically responsible for it produces zero meaningful revenue. Identify the named distributor rep before signing the distribution agreement, not after.

Failure 3: Launch coincides with regulatory uncertainty. Pending or contested regulatory matters (a Notified Body audit not closed, a pending MFDS RAI response, a pending FDA inspection finding) should not coincide with launch. Resolve regulatory issues first, then launch.

Download

Download the 90-Day Launch Playbook PDF — includes editable Excel companions for the day-by-day calendar, sales enablement asset checklist, and metrics dashboard.

Where Leanabl Plugs In

For startups wanting structured launch support, Marketing Assets handles the asset production with regulatory review built in. Commercial Operations handles the post-launch operational stabilization. For Korean-specific launch readiness, Korea Full Market Authorization extends the playbook with MFDS, KGMP, and Korean commercial requirements.